EMEA-002978-PIP01-21
Key facts
Invented name |
Enhertu
|
Active substance |
trastuzumab deruxtecan
|
Therapeutic area |
Oncology
|
Decision number |
P/0275/2021
|
PIP number |
EMEA-002978-PIP01-21
|
Pharmaceutical form(s) |
All pharmaceutical forms
|
Condition(s) / indication(s) |
Treatment of lung cancer
|
Route(s) of administration |
All routes of administration
|
Contact for public enquiries |
Daiichi Sankyo Europe GmbH
E-mail: service@daiichi-sankyo.eu
Tel.: +49 8978080 |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|